Study guide

1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

Key Takeaways Explain This Topic AI

Prader-Willi syndrome results from lack of paternally expressed genes at 15q11-q13; Angelman syndrome results from lack of maternally expressed UBE3A in neurons—same region, opposite parental origin

Mechanisms for PWS/Angelman include deletion, uniparental disomy (UPD), imprinting defects, and (for Angelman) UBE3A variants—each mechanism changes recurrence risk counseling

Methylation analysis at 15q11-q13 is a common first-line screen that detects deletions, UPD, and imprinting defects but does not by itself distinguish among those mechanisms

Beckwith-Wiedemann syndrome (11p15.5 overgrowth/tumor predisposition) and Russell-Silver syndrome (growth restriction) are imprinting disorders with overlapping loci but opposite growth phenotypes

  • CGC exam traps hinge on parental origin: maternal UPD15 → PWS; paternal UPD15 → Angelman; do not invert them
  • Last updated: August 2026

1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

Quick Answer: Imprinted genes are expressed from only one parental allele. Prader-Willi (PWS) = missing paternal 15q11-q13 contribution; Angelman (AS) = missing maternal UBE3A function. Start many evaluations with methylation analysis , then determine mechanism (deletion vs UPD vs imprinting defect ± UBE3A sequencing) because recurrence risk depends on mechanism . Beckwith-Wiedemann (BWS) and Russell-Silver (RSS) are the classic 11p15 growth-opposite pair.

This is a perennial CGC trap topic: same cytogenetic band, opposite syndromes, opposite parental origins.

Genomic Imprinting in One Counseling Paragraph

Imprinting is an epigenetic parent-of-origin mark (often DNA methylation and related chromatin states) set in gametogenesis so that certain genes are expressed only from the maternal or only from the paternal allele. Disease occurs when the only active copy is lost—by deletion of that allele, UPD that duplicates the silent parental chromosome, an imprinting center defect, or (sometimes) a gene variant on the active allele.

  • Term Meaning for counseling
  • Imprinted locus Parent-of-origin–dependent expression
  • Uniparental disomy (UPD) Both chromosome copies from one parent
  • Imprinting center (IC) Regulatory region controlling the imprint mark

Methylation test Reads the epigenetic signature; abnormal pattern = disease-range result needing mechanism workup

  • Prader-Willi vs Angelman (15q11-q13)
  • Phenotype Essentials
  • Prader-Willi syndrome Angelman syndrome
  • Core cause Lack of paternally expressed genes in 15q11-q13 Lack of maternally expressed UBE3A in neurons

Infancy Severe hypotonia, poor feeding, failure to thrive Often normal birth growth; feeding may be poor; developmental delay emerges

Later childhood Hyperphagia, obesity risk, intellectual disability, hypogonadism, behavioral rigidity Severe developmental disability, minimal/absent speech, gait ataxia, happy demeanor/laughter, seizures, microcephaly

  • Inheritance cue Missing paternal contribution Missing maternal UBE3A contribution
  • Mechanisms and Recurrence (Memorize the Logic)

Mechanism PWS result Angelman result Typical recurrence if parents unaffected*

Deletion of 15q11-q13 Paternal deletion → PWS Maternal deletion → AS Usually low if parental studies normal; higher if parent carries rearrangements rare

UPD Maternal UPD 15 → PWS Paternal UPD 15 → AS Usually low (sporadic nondisjunction-related), not 50%

Imprinting defect Paternal imprint fails → PWS Maternal imprint fails → AS May be higher if a parental imprinting-center microdeletion is present

Gene variant — Maternal UBE3A pathogenic variant → AS Up to 50% if mother carries the variant

*Always individualize after laboratory mechanism assignment; the table is the board-level skeleton.

Highest-yield trap pair:

  • Maternal UPD15 → PWS (two maternal chromosomes, no paternal imprint)
  • Paternal UPD15 → Angelman (two paternal chromosomes, no maternal UBE3A expression)

If you reverse these on an exam item, you lose the question.

Testing Strategy at 15q

Methylation analysis (e.g., SNRPN methylation) — abnormal in deletion, UPD, and imprinting defects for PWS/AS; efficient first-line when phenotype fits.

If methylation is abnormal → define mechanism : deletion analysis (FISH/CMA/MLPA), UPD studies, imprinting-center analysis as indicated.

If methylation is normal but Angelman remains likely → UBE3A sequencing (methylation-negative Angelman is often UBE3A -related).

Normal methylation makes classic PWS unlikely; rethink the differential.

Why methylation alone is not enough for recurrence counseling: An abnormal methylation result confirms an imprinting disorder pattern but does not tell you whether the cause was deletion, UPD, or IC defect—and those have different family risks.

Beckwith-Wiedemann Syndrome (BWS)

BWS is an overgrowth and tumor-predisposition imprinting disorder, primarily involving 11p15.5 (IGF2/H19 and KCNQ1OT1/CDKN1C regulation).

  • Feature cluster Examples
  • Growth Macrosomia, macroglossia, hemihyperplasia
  • Abdominal wall Omphalocele, umbilical hernia
  • Neonatal Hypoglycemia (hyperinsulinism)
  • Lateralized overgrowth Hemihyperplasia—tumor risk counseling still applies

Tumors Increased risk of Wilms tumor, hepatoblastoma → protocolized surveillance (AFP, abdominal ultrasound per current guidelines)

Mechanisms (conceptual): gain of paternal methylation marks / paternal UPD 11p15, loss of maternal IC2 methylation, CDKN1C variants, and others. Recurrence risk is usually low for sporadic epigenetic defects but can be higher with genomic alterations or maternally inherited CDKN1C variants—mechanism matters again.

Russell-Silver Syndrome (RSS / Silver-Russell)

RSS presents with prenatal and postnatal growth restriction , relative macrocephaly in many, body asymmetry, and feeding difficulties—clinically opposite to BWS growth excess.

  • Molecular theme Association
  • 11p15.5 Hypomethylation at H19/IGF2 IC1 (paternal) — common identifiable cause
  • Chromosome 7 Maternal UPD 7 in a subset
  • Other Various rarer genetic causes; clinical diagnosis still used when molecularly negative

Counsel growth supports, endocrine evaluation as indicated, and asymmetry monitoring. Do not treat RSS as “mild BWS”—the growth vectors and molecular signatures differ.

BWS vs RSS Comparison Table

  • Beckwith-Wiedemann Russell-Silver
  • Growth Overgrowth Undergrowth
  • Key region 11p15.5 imprinting 11p15.5 and/or mat UPD7

Classic adjuncts Macroglossia, omphalocele, hypoglycemia, tumor risk Relative macrocephaly, asymmetry, feeding issues

Counseling emphasis Tumor surveillance + mechanism-specific recurrence Growth/nutrition + mechanism-specific recurrence

Prenatal and Postnatal Counseling Angles

Prenatal: BWS may be suggested by omphalocele, macroglossia, macrosomia, or placental mesenchymal dysplasia clues; RSS by severe IUGR with relative macrocephaly pattern. Molecular confirmation of imprinting disorders can be complex on prenatal samples—coordinate with labs experienced in methylation/UPD assays and discuss limitations.

Postnatal PWS: neonatal hypotonia/poor feeding → later hyperphagia planning, endocrine/obesity management, GH consideration per specialists. Postnatal Angelman: developmental disability, seizure management, communication supports. Avoid promising speech outcomes that the natural history rarely delivers; focus on augmentative communication.

Session Checklist for Imprinting Items

Identify the syndrome phenotype (PWS vs AS vs BWS vs RSS).

State the parent-of-origin rule in one sentence.

Order thinking: methylation screen → mechanism → recurrence .

Never quote 50% recurrence for UPD-related PWS/AS without a genomic reason to do so.

For BWS, explicitly address tumor surveillance as part of natural-history counseling.

If Domain 1C chromosomal conditions are a three-legged stool, aneuploidy is leg one, microdeletions leg two, and imprinting—parent-of-origin epigenetics—is leg three. Boards love to kick that third leg.